Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
27 mars 2024 08h00 HE
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World...
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20 mars 2024 08h00 HE
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that the Compensation Committee of the Board of Directors...
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
14 mars 2024 16h01 HE
|
Vaxart, Inc.
Significant progress made in preparing for a Phase 2b study evaluating Vaxart’s oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator Topline data from Phase 1 norovirus study...
Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14
07 mars 2024 08h00 HE
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the full year ended...
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
06 mars 2024 08h00 HE
|
Vaxart, Inc.
Michael J. Finney, Ph.D. to Continue as Chairman of the Board of Directors SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”)...
Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge
05 févr. 2024 08h00 HE
|
Vaxart, Inc.
— Data served as foundation for current vaccine candidate for planned Phase 2 research — Vaxart vaccine candidates elicited strong antigen-specific serum IgG and IgA with neutralizing activity...
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
19 janv. 2024 08h30 HE
|
Vaxart, Inc.
- 10,000-subject Phase 2b study would evaluate Vaxart’s next generation oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator - - Project NextGen is a $5 billion initiative by...
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
16 janv. 2024 09h25 HE
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has entered into a common stock purchase agreement with RA Capital Management for...
Vaxart, Inc. Announces Management Change
16 janv. 2024 09h22 HE
|
Vaxart, Inc.
Chief Executive Officer Andrei Floroiu Resigns Chair Michael J. Finney, Ph.D. to Serve as Interim Chief Executive Officer SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxart,...
Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
21 déc. 2023 08h00 HE
|
Vaxart, Inc.
On track to report topline data by the end of 2024 SOUTH SAN FRANCISCO, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has completed enrollment and...